gurufocus.com · 16 jul

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR N

prnewswire.com · 16 jul

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

fool.com · 12 jul

Kymera's CEO Sold $6 Million in Stock After a 170% Run

According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock holdings by 7%, leaving a residual direct position of 667,000 shares.

globenewswire.com · 7 jul

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass.

globenewswire.com · 7 jul

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Elizabeth Laws, Ph.D.

seekingalpha.com · 3 jul

Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)

Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5bn cash position. KT-621, an oral STAT6 degrader for atopic dermatitis, has accelerated Phase 2b timelines with topline data now expected by year-end 2026. KT-621's oral administration and promising early efficacy/safety data position KYMR to challenge injectable incumbents in a multi-billion dollar market.

seekingalpha.com · 3 jul

Kymera: Building Toward A Defining 2H26 Moment

Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection point. KT-621, a first-in-class oral STAT6 degrader, targets large, expanding markets in atopic dermatitis and other type 2 inflammatory diseases. Rapid trial enrollment, a strong balance sheet ($1.55B cash), and external validation position KYMR for potential high-value partnerships and lifecycle expansion.

zacks.com · 1 jul

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.